Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery
- 1 November 1999
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 62 (1-2), 25-31
- https://doi.org/10.1016/s0168-3659(99)00034-6
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Role of P-Glycoprotein and Cytochrome P450 3A in Limiting Oral Absorption of Peptides and Peptidomimetics†Journal of Pharmaceutical Sciences, 1998
- The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.Journal of Clinical Investigation, 1998
- Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression.Journal of Clinical Investigation, 1997
- Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes: Major role of CYP3ABiochemical Pharmacology, 1997
- Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug deliveryJournal of Controlled Release, 1996
- Vinyl Sulfones as Mechanism-Based Cysteine Protease InhibitorsJournal of Medicinal Chemistry, 1995
- Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapyMolecular Carcinogenesis, 1995
- BIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTERAnnual Review of Biochemistry, 1993
- Cyclosporin‐erythromycin interaction in renal transplant patients.British Journal of Clinical Pharmacology, 1989
- Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man.Journal of Clinical Investigation, 1987